Skip to main navigation Skip to search Skip to main content

Oxidative stress induced by Etoposide anti-cancer chemotherapy drives the emergence of tumor-associated bacteria resistance to fluoroquinolones

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

46 Downloads (CityUHK Scholars)

Abstract

Introduction:  Antibiotic-resistant bacterial infections, such as Pseudomonas aeruginosa and Staphylococcus aureus, are prevalent in lung cancer patients, resulting in poor clinical outcomes and high mortality. Etoposide (ETO) is an FDA-approved chemotherapy drug that kills cancer cells by damaging DNA through oxidative stress. However, it is unclear if ETO can cause unintentional side effects on tumor-associated microbial pathogens, such as inducing antibiotic resistance.

Objectives:  We aimed to show that prolonged ETO treatment could unintendedly confer fluoroquinolone antibiotic resistance to P. aeruginosa, and evaluate the effect of tumor-associated P. aeruginosa on tumor progression.

Methods:   We employed experimental evolution assay to treat P. aeruginosa with prolonged ETO exposure, evaluated the ciprofloxacin resistance, and elucidated the gene mutations by DNA sequencing. We also established a lung tumor-P. aeruginosa bacterial model to study the role of ETO-evolved intra-tumoral bacteria in tumor progression using immunostaining and confocal microscopy.

Results:  ETO could generate oxidative stress and lead to gene mutations in P. aeruginosa, especially the gyrase (gyrA) gene, resulting in acquired fluoroquinolone resistance. We further demonstrated using a microfluidic-based lung tumor-P. aeruginosa coculture model that bacteria can evolve ciprofloxacin (CIP) resistance in a tumor microenvironment. Moreover, ETO-induced CIP-resistant (EICR) mutants could form multicellular biofilms which protected tumor cells from ETO killing and enabled tumor progression.

Conclusion:  Overall, our preclinical proof-of-concept provides insights into how anti-cancer chemotherapy could inadvertently allow tumor-associated bacteria to acquire antibiotic resistance mutations and shed new light on the development of novel anti-cancer treatments based on anti-bacterial strategies.

© 2023 The Authors. Published by Elsevier B.V. on behalf of Cairo University.
Original languageEnglish
Pages (from-to)33-44
JournalJournal of Advanced Research
Volume55
Online published21 Feb 2023
DOIs
Publication statusPublished - Jan 2024

Funding

The City University of Hong Kong (9610430, 7005208, 7005464, 7020002, 9667220); Hong Kong Center for Cerebro-Cardiovascular Health Engineering (COCHE); Pneumoconiosis Compensation Fund Board (9211276 and ZJN2); Research Grants Council (RGC 9048206 and 11204317); The Hong Kong Polytechnic University, Department of Applied Biology and Chemical Technology Startup Grant (BE2B), Departmental General Research Fund (UALB), One-line account (ZVVV), Environmental and Conservation Fund (ECF48/2019 and ECF-84/2021), Health and Medical Research Fund (HMRF-201903032), State Key Laboratory of Chemical Biology and Drug Discovery Fund (1-BBX8); and the Hetao ShenzhenHong Kong Science and Technology Innovation Cooperation Zone Shenzhen Park Project (HZQB-KCZYZ-2021017).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Publisher's Copyright Statement

  • This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/

RGC Funding Information

  • RGC-funded

Fingerprint

Dive into the research topics of 'Oxidative stress induced by Etoposide anti-cancer chemotherapy drives the emergence of tumor-associated bacteria resistance to fluoroquinolones'. Together they form a unique fingerprint.

Cite this